![Banner-Brand-Element_1800x204_ocker_v1](https://biocrates.com/wp-content/uploads/2020/07/Banner-Brand-Element_1800x204_ocker_v1.jpg)
biocrates blog
Applications of metabolomics
Mass spectrometry in metabolomics – From methodologies to applications
Metabolomics highlights the significant role of microbial communities in human health, driving a paradigm shift towards towards personalized, proactive healthcare.
Butyric acid – Metabolite of the month
Metabolite of the month is your sneak peek into the world of metabolomics. In this month´s article, we took a closer look at butyric acid, which is one of three common SCFAs in the human gut.
Choline – Metabolite of the month
The metabolite of this month is choline, implicated in various aspects of neurological and cardiovascular health and function.
Does metabolomics have a place in microbiome research?
Metabolomics highlights the significant role of microbial communities in human health, driving a paradigm shift towards towards personalized, proactive healthcare.
Trimethylamine N-oxide (TMAO) – Metabolite of the month
Trimethylamine oxide (TMAO), which has been suggested to be a “bad” metabolite
3-indoleacetic acid (3-IAA) – Metabolite of the month
The metabolite of this month is 3-IAA, known as the most common plant growth hormone.
p-cresol sulfate – Metabolite of the month
The metabolite of this month is p-cresol sulfate, a sulfate conjugate of the bacterial metabolite p-cresol, which is a uremic toxin.
Alpha-pinene – Metabolite of the month
As one of the metabolites responsible for the smell of conifers, alpha-pinene is a fitting choice for our festive Metabolite of the month.
Melatonin – Metabolite of the month
Our metabolite of the month melatonin is an ancient molecule found in all living organisms from bacteria to humans, with an evolution that can be traced back 2.5 billion years.
Treatment of non-alcoholic fatty liver disease (NAFLD) as a chemopreventive strategy for other chronic disease: a metabolomics perspective
NAFLD is a key player in other chronic diseases – both as a prevalent comorbidity and a contributing factor. Does this mean that treating NAFLD could prevent those conditions?